Evidence map›Paper›PMID 33808815›Full record

ArticleMicroorganisms2021

High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children.

Michael Huber, Peter Werner Schreiber, Thomas Scheier, Annette Audigé, Roberto Buonomano, Alain Rudiger, Dominique L Braun, Gerhard Eich, Dagmar I Keller, Barbara Hasse and 5 more

Abstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Validation of RT-qPCR test for SARS-CoV-2 in saliva specimens.Journal of infection and public health · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael HuberInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-0384-0000
Peter Werner SchreiberDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Thomas ScheierDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-7805-1025
Annette AudigéInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.
Roberto BuonomanoDivision of Infectious Diseases and Hospital Hygiene, Spital Limmattal, 8952 Schlieren, Switzerland.
Alain RudigerDivision of Medicine, Spital Limmattal, 8952 Schlieren, Switzerland.
Dominique L BraunDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-4036-1030
Gerhard EichDivision of Infectious Diseases, Hospital Hygiene and Occupational Medicine, Stadtspital Triemli, 8063 Zurich, Switzerland.
Dagmar I KellerEmergency Department, University Hospital Zurich, 8091 Zurich, Switzerland.
Barbara HasseDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Jürg BöniInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0001-7925-4852
Christoph BergerDivision of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, 8032 Zurich, Switzerland.ORCID 0000-0002-2373-8804
Huldrych F GünthardInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-1142-6723
Amapola ManriqueInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.ORCID 0000-0003-3982-398X
Alexandra TrkolaInstitute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland.

Funding

Bundesamt für Gesundheit NARoche Diagnostics NAUZH Foundation NA
6 · The paper itself

Abstract

Rising demands for repetitive SARS-CoV-2 screens and mass testing necessitate additional test strategies. Saliva may serve as an alternative to nasopharyngeal swab (NPS) as its collection is simple, non-invasive and amenable for mass- and home testing, but its rigorous validation, particularly in children, is missing. We conducted a large-scale head-to-head comparison of SARS-CoV-2 detection by RT-PCR in saliva and NPS of 1270 adults and children reporting to outpatient test centers and an emergency unit. In total, 273 individuals were tested positive for SARS-CoV-2 in either NPS or saliva. SARS-CoV-2 RT-PCR results in the two specimens showed a high agreement (overall percent agreement = 97.8%). Despite lower viral loads in the saliva of both adults and children, detection of SARS-CoV-2 in saliva fared well compared to NPS (positive percent agreement = 92.5%). Importantly, in children, SARS-CoV-2 infections were more often detected in saliva than NPS (positive predictive value = 84.8%), underlining that NPS sampling in children can be challenging. The comprehensive parallel analysis reported here establishes saliva as a generally reliable specimen for the detection of SARS-CoV-2, with particular advantages for testing children, that is readily applicable to increase and facilitate repetitive and mass testing in adults and children.

Indexed as

childrenPCRsalivaSARS-CoV-2

Identifiers

PMID33808815
PMCPMC8003663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.